

Disclosure Purpose: 21-13468

## Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Medical Director <i>Additional Information:</i>		<i>Position Description:</i>
Pfizer	Stock	Self
<i>Additional Information:</i>		

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13468

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Director <i>Additional Information:</i>		<i>Position Description:</i> Clinical Scientist
Pfizer	Stock	Self
<i>Additional Information:</i>		

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-13468

## Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Executive Director <i>Additional Information:</i>		<i>Position Description:</i> Vaccine Researcher
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13468

## Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Vice President and Chief Scientific Officer Viral and RNA Vaccines <i>Additional Information:</i>		<i>Position Description:</i>
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

# Ann Falsey

Disclosure Purpose: 21-13468

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
<a href="#">BioFire Diagnostics, LLC</a>	Grant / Contract	Self
<i>Recipient Name:</i> University of Rochester <i>Grant / Contract Description:</i> Improved diagnostics for respiratory infection <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
<a href="#">Janssen Biotech</a>	Grant / Contract	Self
<i>Recipient Name:</i> University of Rochester <i>Grant / Contract Description:</i> Vaccine and Epidemiology <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
<a href="#">Merck</a>	Grant / Contract	Self
<i>Recipient Name:</i> University of Rochester <i>Grant / Contract Description:</i> Epidemiology of RSV <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
<a href="#">Novavax</a>	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Additional Information:</i>		<i>Description:</i> COVID Vaccine DSMB
<a href="#">Pfizer</a>	Grant / Contract	Self
<i>Recipient Name:</i> University of Rochester <i>Grant / Contract Description:</i> Vaccine Trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

### Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  
No.
- What is the manuscript title?  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?  
No.

### Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13468

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Grant / Contract	Self
<i>Recipient Name:</i> Cincinnati Children's Hospital Medical Center <i>Grant / Contract Description:</i> Clinical Trial grant for COVID-19 vaccines <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Safety, Immunogenicity, and Efficacy of the BNT162b2 COVID-19 Vaccine in Adolescents
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-13468

## Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Vice President		<i>Position Description:</i> Vaccine Clinical Research and Development Worldwide Research Development and Medical
<i>Additional Information:</i>		
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



**Disclosure Purpose:** 21-13468

## Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> VP Vaccine Clinical Research and Development <i>Additional Information:</i>		<i>Position Description:</i>

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



# Kathrin Jansen

Disclosure Purpose: 21-13468

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> SVP and Head of vaccine R&D <i>Additional Information:</i>		<i>Position Description:</i> head of vaccine R&D
Pfizer	Stock	Self
<i>Additional Information:</i> as a Pfizer employee i hold PFE stock and stock options		

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

**Disclosure Purpose:** 21-13468

## Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Director <i>Additional Information:</i>		<i>Position Description:</i>
Pfizer	Stock	Self
<i>Additional Information:</i>		

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13468

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Executive Director <i>Additional Information:</i> Full time employee		<i>Position Description:</i> Vaccine Clinical Research and Development
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

## Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

3. **Are you the corresponding author?**

Yes.

- a. **Please list the other authors' names here.**

Ann R. Falsey, MD, Robert W. Frenck, Jr., MD, Edward E. Walsh, MD, Judith Absalon, MD, Alejandra Gurtman, MD, Stephen Lockhart, DM, Ruth Bailey, BSc, Kena A. Swanson, PhD, Xia Xu, PhD, Kenneth Koury, PhD, Warren Kalina, PhD, David Cooper, PhD, Jing Zou, PhD, Xuping Xie, PhD, Hongjie Xia, PhD, Özlem Türeci, MD, Eleni Lagkadinou, MD, PhD, Kristin R. Tompkins, BSc, Pei-Yong Shi, PhD, Kathrin U. Jansen, PhD, Uğur Şahin, MD, Philip R. Dormitzer, MD, PhD, and William C. Gruber, MD

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13468

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Executive Director <i>Additional Information:</i>		<i>Position Description:</i> Head of Statistics and Modeling, Vaccine Clinical Research and Development
Pfizer	Stock	Self
<i>Additional Information:</i>		

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

# Eleni Lagkadinou

Disclosure Purpose: 21-13468

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
BioNTech SE	Employment	Self
<i>Title:</i> Vice President Clinical Research <i>Additional Information:</i>		<i>Position Description:</i>

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

# Stephen Lockhart

Disclosure Purpose: 21-13468

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Vice President <i>Additional Information:</i>		<i>Position Description:</i> Clinical Research Head Vaccines Europe and Asia Pacific
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

# Ugur Sahin

Disclosure Purpose: 21-13468

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
biontech	Fiduciary Officer	Self
<i>Official Title:</i> Chief Executive Officer, Co-Founder		<i>Position Description:</i> Member of the Board
<i>Additional Information:</i>		
biontech	Stock	Self
<i>Additional Information:</i>		
biontech	Stock Option	Self
<i>Additional Information:</i>		

### Intellectual Property

Type	Is Licensed	Interest Held By
Patent - 3 UTR Sequences for stabilisation of mRNA	Yes	Self
<i>Description:</i> 3 UTR Sequences for stabilisation of mRNA		<i>Patent Number:</i> EPPCT/EP2015/073180, US 20190071682
<i>Patent Status:</i> Pending		<i>Patent Holder:</i> Previous Institution
<i>Filing Jurisdiction:</i> USA		<i>Additional Information:</i> I am co-inventors on various patents on RNA Technologies, both pending and granted, which have been filed over a period of 10+ years, some of which are licensed to third parties.
<i>Licensees:</i>		Jurisdictions are Broad including US, EU, Asia.
<b>Licensee</b>	<b>Title</b>	<b>Date</b>
biontech		

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  
No.
- What is the manuscript title?  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

# Pei-Yong Shi

Disclosure Purpose: 21-13468

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
<a href="#">Pfizer Inc.</a>	Grant / Contract	Self

*Recipient Name:* Pei-Yong Shi  
*Grant / Contract Description:* Contract  
*Additional Information:* Sample testing

*Recipient Type:* Institution  
*Grant / Contract Purpose:* Research

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



# Kena Swanson

Disclosure Purpose: 21-13468

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Director, Viral Vaccines <i>Additional Information:</i>		<i>Position Description:</i> vaccine research and development
Pfizer	Stock	Self
<i>Additional Information:</i>		

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

# Kristin Tompkins

**Disclosure Purpose:** 21-13468

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
2. **What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
3. **Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13468

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
biontech	Employment	Self
<i>Title:</i> Chief Medical Officer <i>Additional Information:</i>		<i>Position Description:</i> Board member, CO-founder
biontech	Fiduciary Officer	Self
<i>Official Title:</i> Chief Medical Officer <i>Additional Information:</i> also spouse is co-founder and board member (Chief Executive Officer) of Biontech		<i>Position Description:</i> board member, co-founder
biontech	Fiduciary Officer	Spouse/Partner
<i>Official Title:</i> CEO <i>Additional Information:</i>		<i>Position Description:</i>
biontech	Stock	Spouse/Partner
<i>Additional Information:</i> founder, shareholder		
biontech	Stock Option	Self
<i>Additional Information:</i> self and spouse have stock Options. spouse has stock		

### Intellectual Property

Type	Is Licensed	Interest Held By						
Patent - Modifications of RNA leading to increased transc ...	Yes	Self						
<i>Description:</i> Modifications of RNA leading to increased transcript stability and translational efficiency <i>Patent Status:</i> Pending <i>Filing Jurisdiction:</i> USA <i>Licensees:</i>		<i>Patent Number:</i> EP1934345B9, DE102005046490.4 <i>Patent Holder:</i> Current Institution  <i>Additional Information:</i> self and spouse are co-inventors on patents on RNA Tech						
<table border="1"> <thead> <tr> <th>Licensee</th> <th>Title</th> <th>Date</th> </tr> </thead> <tbody> <tr> <td>biontech</td> <td></td> <td></td> </tr> </tbody> </table>	Licensee	Title	Date	biontech				
Licensee	Title	Date						
biontech								

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  
No.
- What is the manuscript title?  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13468

## Summary of Interests

## Company or Organization

Entity	Type	Interest Held By
<a href="#">AstraZeneca</a>	Grant / Contract	Self
<i>Recipient Name:</i> University of Rochester <i>Grant / Contract Description:</i> Investigator for vaccine trial <i>Additional Information:</i> salary support for investigator role in vaccine study		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
<a href="#">GlaxoSmithKline</a>	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Additional Information:</i> Hourly payment for work related to DSMB		<i>Description:</i> DSMB for influenza vaccine study
<a href="#">Janssen Biotech</a>	Grant / Contract	Self
<i>Recipient Name:</i> Edward Walsh <i>Grant / Contract Description:</i> Vaccine Study <i>Additional Information:</i> grant support for salary as co-investigator		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research
<a href="#">Merck</a>	Grant / Contract	Self
<i>Recipient Name:</i> Edward Walsh <i>Grant / Contract Description:</i> Separate grants to study epidemiology of Respiratory Syncytial Virus and COVID-19 hospitalizations		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i> Salary support as PI for research project
<a href="#">Novavax</a>	Grant / Contract	Self
<i>Recipient Name:</i> Pfizer <i>Grant / Contract Description:</i> Vaccine research <i>Additional Information:</i> salary support as PI		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research
<a href="#">Pfizer Inc.</a>	Grant / Contract	Self
<i>Recipient Name:</i> Edward Walsh <i>Grant / Contract Description:</i> Vaccine study <i>Additional Information:</i> Salary support for PI role in vaccine study		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

# Hongjie Xia

Disclosure Purpose: 21-13468

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
2. **What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
3. **Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

# Xuping Xie

**Disclosure Purpose:** 21-13468

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
2. **What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
3. **Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

# Xia Xu

Disclosure Purpose: 21-13468

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Sr. Director, Vaccine Statistics <i>Additional Information:</i>		<i>Position Description:</i> Design, conduct, and analysis of vaccine clinical trials

## Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
- What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
- Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.



# Jing Zou

**Disclosure Purpose:** 21-13468

## Summary of Interests

I do not have any interests to disclose at this time.

## Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**  
No.
2. **What is the manuscript title?**  
Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
3. **Are you the corresponding author?**  
No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.